Provided by Tiger Trade Technology Pte. Ltd.

Entera Bio Ltd.

2.90
-0.0500-1.69%
Post-market: 2.900.00000.00%16:10 EDT
Volume:256.21K
Turnover:736.21K
Market Cap:501.70M
PE:-8.20
High:3.09
Open:2.94
Low:2.80
Close:2.95
52wk High:4.20
52wk Low:0.9100
Shares:173.00M
Float Shares:138.87M
Volume Ratio:0.83
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3536
EPS(LYR):-0.2476
ROE:-138.92%
ROA:-45.98%
PB:69.05
PE(LYR):-11.71

Loading ...

Entera Bio Shareholders Approve Authorized Share Increase at Annual Meeting

Reuters
·
Jul 17

America’s Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX)

TIPRANKS
·
Jul 08

3 Promising Penny Stocks With Market Caps Under $600M

Simply Wall St.
·
Jun 23

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:17 PM

Reuters
·
Jun 23

Entera Bio Advances Oral Osteoporosis Drug EB613 With Positive FDA Feedback

MT Newswires Live
·
Jun 22

Entera Bio gets FDA backing for 12-month Phase 3 EB613 osteoporosis trial in 750 women

Reuters
·
Jun 22

After Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story?

TIPRANKS
·
Jun 18

Entera Bio and Opko Health present preclinical data for oral peptides

TIPRANKS
·
Jun 16

Entera Bio reports preclinical EB612 data, targets late-2026 IND filing for hypoparathyroidism program

Reuters
·
Jun 16

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

GlobeNewswire
·
Jun 16

Entera Bio reports Phase 1 data showing single-tablet EB613 matches Forteo PK/PD profile

Reuters
·
Jun 15

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

GlobeNewswire
·
Jun 15

Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)

TIPRANKS
·
Jun 01

Entera Bio announces annual shareholder meeting notice

Reuters
·
May 15

Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Entera Bio (ENTX) and Merck & Company (MRK)

TIPRANKS
·
May 11

Entera Bio Faces Elevated Operational Risks Amid Escalating Middle East Geopolitical Tensions

TIPRANKS
·
May 10

Entera Bio files to sell 19.57M ordinary shares for holders

TIPRANKS
·
May 09

Israel's Entera Bio Q1 net loss widens on higher R&D costs

Reuters
·
May 09

Entera Bio Q1 FY26 net loss widens to $3.5 million

Reuters
·
May 09

Entera Bio Q1 EPS $(0.07) Beats $(0.08) Estimate

Benzinga Earnings
·
May 09